Technology Review - Published By MIT
Advertisement
TO READ THIS STORY - you must have a paid subscription to Technology Review OR you can purchase special archive reading credits here. Choose from these great offers below.
I'm a paid subscriber please
log me in
I want to purchase this article for
only $1.99
(requires login)
I want to purchase five articles for
only $7.99
(requires login)
I want to buy
1 Year TOTAL Access for
only $24.95
(requires login)

Please note: Click here if you are currently a Technology Review print or digital subscriber and do not have access to this article.

May 2004

Testing New TB Vaccines

By Corie Lok

Tuberculosis is the world's deadliest infectious disease, sickening eight million people and killing two million every year. A century-old vaccine prevents childhood forms of the disease. But there's a desperate need for a vaccine that's effective against the adult form of the disease, which is highly contagious and is growing resistant to drug treatment. Renewing hope on this front, two human trials of vaccines that could be protective against the adult form of the disease began in the United States earlier this year.

Select from the choices above
to read the entire article.


Log In

Forgot your password?     Register »
Advertisement

Videos

Laser-Triggered Chemical Reactions
Advertisement
Advertisement
Advertisement
Subscribe to Technology Review's daily e-mail update. Enter your e-mail address

TECHNOLOGY RESOURCES

More Technology News from Forbes

Advertisement
MIT Massachusetts Institute of Technology © 2009 Technology Review. All Rights Reserved.